Evidence map›Paper›PMID 42588092›Full record

ReviewNutrients2026

Gut Microbiome Changes in Preclinical Alzheimer's Disease.

D M Sithara Dissanayaka, Stephanie R Rainey-Smith, Hamid R Sohrabi, Thilini N Jayasinghe, Vincent Ho, Vijay Jayasena, Kevin Taddei, Colin L Masters, Ralph N Martins, W M A D Binosha Fernando

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

D M Sithara DissanayakaCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-8266-8973
Stephanie R Rainey-SmithCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0001-7328-9624
Hamid R SohrabiAlzheimer's Research Australia, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA 6009, Australia.ORCID 0000-0001-8017-8682
Thilini N JayasingheSydney Dental School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0000-0002-3374-0916
Vincent HoSchool of Medicine, Western Sydney University, Campbelltown Hospital, Campbelltown, NSW 2560, Australia.ORCID 0000-0003-3127-2933
Vijay JayasenaSchool of Science and Health, Western Sydney University, M15, Room G54, Locked Bag 1797, Penrith, NSW 2751, Australia.ORCID 0000-0001-8681-0626
Kevin TaddeiCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-8106-7957
Colin L MastersMedical School, University of Western Australia, Perth, WA 6009, Australia.ORCID 0000-0003-3072-7940
Ralph N MartinsCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-4828-9363
W M A D Binosha FernandoCentre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-8364-7808

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that develops many years before clinical symptoms appear. The biological changes involved in the earliest stages remain poorly understood, particularly during the preclinical stage. Our previous work has identified gradual gut microbial and metabolic changes during this stage, suggesting these may represent early biological shifts that precede disease progression. Recent studies suggest that the gut microbiome may contribute to early AD processes through its effects on immune regulation, metabolism, and gut-brain communication. Changes in gut microbial composition, including reduced levels of short-chain fatty acid (SCFA)-producing bacteria, such as

Indexed as

Alzheimer DiseaseGastrointestinal MicrobiomeAnimalsBrainDietFatty Acids, VolatileHumansFatty Acids, VolatileAlzheimer’s diseasedietary patternsgut–brain axisgut microbiomeneuroinflammationpreclinicalshort-chain fatty acids

Identifiers

PMID42588092
PMCPMC13467938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.